Acta poloniae pharmaceutica 2010-01-01

Inhibition of DNA topoisomerases I and II by G3 PAMAM-NH2 dendrimer-modified digoxin and proscillaridin A conjugates in a cell free system.

Katarzyna Winnicka, Anna Bielawska, Krzysztof Bielawski

Index: Acta Pol. Pharm. 67(6) , 630-4, (2010)

Full Text: HTML

Abstract

Two modified glycosides--digoxin and proscillaridin A conjugated to a generation 3 of polyamidoamine dendrimer (G3 PAMAM-NH2) were evaluated as DNA topoisomerase II inhibitors. The ability of these compounds (PAMAM-Dig and PAMAM-Prosc) to inhibit topoisomerase I and II activity was quantified by measuring the action on supercoiled DNA substrate as a function of increasing concentration of the test compounds by the use of agarose gel electrophoresis. The obtained results suggest that a conjugation of the modified glycosides with G3 PAMAM-NH2 significantly improved the ability of the parent compounds to an inhibition of DNA topoisomerases.

Related Compounds

  • Proscillaridin A

Related Articles:

Pulse pressure correlates in humans with a proscillaridin A immunoreactive compound.

1996-05-01

[Hypertension 27(5) , 1073-8, (1996)]

Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.

2009-11-01

[J. Nat. Prod. 72 , 1969-74, (2009)]

Role of endogenous cardiac glycosides in the spontaneously hypertensive rat--antagonism by active immunization.

1996-01-01

[Am. J. Hypertens. 9(1) , 81-5, (1996)]

Specific anti-digoxin Fab fragments: an available antidote for proscillaridin and scilliroside poisoning?

1990-05-01

[Hum. Exp. Toxicol. 9(3) , 191-3, (1990)]

Studies on cardiac ingredients of plants. IX. Chemical transformation of proscillaridin by utilizing its 1,4-cycloadducts as key compounds and biological activities of their derivatives.

1992-02-01

[Chem. Pharm. Bull. 40(2) , 327-32, (1992)]

More Articles...